Neoadjuvant chemotherapy of irinotecan, 5-fluorouracil and leucovorin in patients with advanced rectal cancer. Report of two cases

Hirotoshi Hasegawa, Masahiko Watanabe, Hideo Baba, Kentaro Yoshinare, Makio Mukai, Tetsuro Kubota, Masaki Kitajima

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We report on two patients with T3N1 rectal cancer treated with a combination of irinotecan, 5-fluorouracil and leucovorin as neoadjuvant chemotherapy. On days 1, 8 and 15 of this 4-week cycle, leucovorin (250mg/m2) was administered in a 2-hour intravenous infusion, followed by 5-fluorouracil (500mg/ m2) in a 10-min intravenous bolus, and then irinotecan (80mg/m2) in a 90-min intravenous infusion. During the chemotherapy, no grade 3-4 texicities were observed. Two weeks after the completion of 2 cycles of this regimen, both patients underwent surgery without postoperative complications. The responses were one pathological and one macroscopic complete response. Both patients with T3 tumors were down-staged to pT0 and pT2, respectively. As for the N stage, both patients were down-staged to pN0. The combination of irinotecan/5-fluorouracil/ leucovorin appears to be feasible and effective, and to have a potential as an optimal neoadjuvant therapy in patients with advanced rectal cancer.

Original languageEnglish
Pages (from-to)891-893
Number of pages3
JournalHepato-Gastroenterology
Volume49
Issue number46
Publication statusPublished - 2002

    Fingerprint

Keywords

  • 5-Fluorouracil
  • Irinotecan
  • Leucovorin
  • Neoadjuvant chemotherapy
  • Rectal cancer

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Hasegawa, H., Watanabe, M., Baba, H., Yoshinare, K., Mukai, M., Kubota, T., & Kitajima, M. (2002). Neoadjuvant chemotherapy of irinotecan, 5-fluorouracil and leucovorin in patients with advanced rectal cancer. Report of two cases. Hepato-Gastroenterology, 49(46), 891-893.